The long and winding road toward a short XRP exchange-traded fund grew longer this week, as Teucrium's proposed inverse product was reportedly postponed once more. The delay, characterized in an unconfirmed tip as the 19th such setback, has left the product's timeline in limbo with no revised date publicly disclosed.
Teucrium's Short XRP ETF Hits Another Snag as Launch Date Slips Again
The long and winding road toward a short XRP exchange-traded fund grew longer this week, as Teucrium's proposed inverse product was reportedly postponed once more. The delay, characterized in an unconfirmed tip as the 19th such setback,…
finance.biggo.com
Publisher
Sep 14, 2026 at 6:06 PM UTC · Updated bir gün önce · 3 dk okuma

Entities
xrp
Market Impact
XRP-12.29%$1.28
Last Updated
bir gün önce
What remains clear is that the issuer has been actively amending its registration documents. SEC EDGAR records show a Form 485BXT filed on September 11, 2026, under Listed Funds Trust, bearing the accession number 0000894189-26-025151. The document name, teucrium485bxt2xshortxrp.htm, points to a fund seeking twice the inverse of XRP's daily price movement. An earlier filing with the same short-XRP document name appeared on August 14, 2026.
Form 485BXT is a post-effective amendment used to delay the effectiveness of a registration statement, a procedural step that typically signals the issuer needs more time before the fund can begin trading. The filings confirm ongoing regulatory engagement but do not, by themselves, establish an SEC approval, rejection, or the specific reason for any postponement.
The count of 19 delays originates from a single headline tip circulating on September 14, 2026, and could not be independently verified against a complete chronology of effective-date amendments. No issuer statement, regulatory order, or confirmed launch date accompanied the report.
Market Context
Article Intelligence
Key Entities
Sponsored
AdNewsLayer Premium
Unlock deeper intelligence.
Ad-free reading, exclusive research, and real-time onchain insights.
Go Premium
